Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportMolecular Targeting Technologies - Radioactive and Nonradioactive Probes: Novel Radioactive Probes

Targeting GRPR-expressing tumors with an 18F-labeled bombesin analog

Ingrid Dijkgraaf, Gerben Franssen, W. McBride, Christopher D'Souza, Charles Smith, David Goldenberg, Wim Oyen and Otto Boerman
Journal of Nuclear Medicine May 2011, 52 (supplement 1) 297;
Ingrid Dijkgraaf
1Nuclear Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gerben Franssen
1Nuclear Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
W. McBride
2Immunomedics, Inc., Morris Plains, NJ
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher D'Souza
2Immunomedics, Inc., Morris Plains, NJ
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Charles Smith
3University of Missouri, Columbia, MO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Goldenberg
4Garden State Cancer Center, Belleville, NJ
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wim Oyen
1Nuclear Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Otto Boerman
1Nuclear Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Article Information

vol. 52 no. supplement 1 297

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Published online November 4, 2014.

Copyright & Usage 
© 2011

Author Information

  1. Ingrid Dijkgraaf1,
  2. Gerben Franssen1,
  3. W. McBride2,
  4. Christopher D'Souza2,
  5. Charles Smith3,
  6. David Goldenberg4,
  7. Wim Oyen1 and
  8. Otto Boerman1
  1. 1Nuclear Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
  2. 2Immunomedics, Inc., Morris Plains, NJ
  3. 3University of Missouri, Columbia, MO
  4. 4Garden State Cancer Center, Belleville, NJ

Statistics from Altmetric.com

Cited By...

  • Citations
  • Google Scholar

This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.

Article usage

Article usage: January 2015 to April 2025

AbstractFullPdf
Jan 2015100
Apr 2015100
May 2015100
Jun 2015300
Jul 2015300
Sep 2015500
Dec 2015300
Feb 2016600
Apr 2016800
Oct 2016300
Nov 2016600
Dec 2016100
Mar 2017200
Apr 2017200
May 2017100
Jun 2017100
Jul 2017300
Aug 2017100
Sep 2017300
Oct 2017500
Nov 2017300
Dec 2017300
Mar 2018100
Sep 2018300
Oct 2018800
Nov 2018200
Dec 2019100
Feb 2020400
Mar 20201400
Apr 2020800
Jul 2020200
Aug 20201100
Sep 20202400
Oct 20201600
Nov 20201500
Dec 2020900
Feb 20211200
Mar 2021500
Apr 2021700
May 20212100
Jun 20211300
Jul 20211900
Aug 20216600
Sep 20211000
Oct 20212700
Nov 20218100
Dec 20213800
Jan 20226900
Feb 20222100
Mar 20222300
Apr 20222600
May 20221900
Jun 2022400
Jul 2022200
Aug 2022200
Nov 2022100
Jan 2023200
Mar 2023200
Apr 2023300
May 2023200
Jun 2023100
Jul 2023200
Aug 2023200
Sep 2023400
Oct 2023100
Nov 2023200
Dec 2023200
Jan 2024800
Mar 2024600
Apr 2024300
May 2024700
Jun 2024200
Jul 2024300
Aug 2024200
Sep 2024200
Oct 2024200
Nov 2024200
Dec 2024400
Jan 2025100
Feb 2025600
Mar 2025200
Apr 2025600
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 52, Issue supplement 1
May 2011
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Targeting GRPR-expressing tumors with an 18F-labeled bombesin analog
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Targeting GRPR-expressing tumors with an 18F-labeled bombesin analog
Ingrid Dijkgraaf, Gerben Franssen, W. McBride, Christopher D'Souza, Charles Smith, David Goldenberg, Wim Oyen, Otto Boerman
Journal of Nuclear Medicine May 2011, 52 (supplement 1) 297;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Targeting GRPR-expressing tumors with an 18F-labeled bombesin analog
Ingrid Dijkgraaf, Gerben Franssen, W. McBride, Christopher D'Souza, Charles Smith, David Goldenberg, Wim Oyen, Otto Boerman
Journal of Nuclear Medicine May 2011, 52 (supplement 1) 297;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Molecular Targeting Technologies - Radioactive and Nonradioactive Probes: Novel Radioactive Probes

  • F-18 labeled bis-dialkylamino-curcuminoid as a potential amyloid-beta imaging agent
  • Labeling of DTPA-BP with Tc-99m and Ga-68 as new phosphorus bone imaging agents
  • Application of click chemistry in the synthesis of 68Ga-labeled agents
Show more Molecular Targeting Technologies - Radioactive and Nonradioactive Probes: Novel Radioactive Probes

Novel Radioactive Probes II: Tumor Probes - Part 1

  • Positron emission tomography imaging of CD105 expression during tumor angiogenesis
  • Dual modality SPECT/near infrared fluorescence (NIRF) imaging of prostate cancer at radiotracer levels through targeting of the prostate-specific membrane antigen (PSMA)
  • 99mTc-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer
Show more Novel Radioactive Probes II: Tumor Probes - Part 1

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire